Engineered immune cells take aim at stubborn lung cancer
NCT ID NCT07744256
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial is testing a new type of cell therapy for adults with small cell lung cancer that has returned or not responded to standard treatments. The therapy uses immune cells called natural killer (NK) cells, engineered to recognize and attack cancer cells through two targets at once. The study will first find the safest dose and best target combination, then expand to see how well it shrinks tumors and controls the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Allogeneic dual-target CAR-NK cells (EB-DART-NK01) with lymphodepleting chemotherapy
- What this could lead to
- If successful, this could provide a new treatment option for people with hard-to-treat small cell lung cancer, potentially improving tumor shrinkage and disease control.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the treatment may not work as hoped or could cause significant side effects. The best approach is still being determined.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New PET scan targets hidden lung cancer cells
- New drug THE-0504 enters human testing for tough cancers
- Gene therapy safety check: 400 cancer patients monitored for years